Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?

Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of... Should measures be taken to reduce the risk of human parvovirus (B 19) infection by transfusion of blood components and clotting factor concentrates? Over the last several years, a seemingly endless array of infectious agents have occasionally been transmitted by blood components andor plasma derivatives. We had thought that human parvovirus (HPV, B19) was responsible only for a self-limited common childhoodexanthem, with a brief period of viremia. It is now known to be a virus that is capable of prolonged viremia,' latency with reactivation,2and possible reinfe~tion.~.~ proporA small tion of persons have serious, sometimes chronic, impaired production of erythroid and, sporadically, other bone marrow cells, as well as manifestations in other systems. In this issue of TRANSFUSION, Luban5makes clear that a great deal can be learned quickly about a virus and its pathogenesis by using the tools of molecular virology. She correctly points out how much more difficult is the definition of the type and variety of recipients for whom HPV infection has the potential to be clinically important. Definition of the number of serious acute and chronic HPV cases, particularly if they are sporadic, depends first upon the physician's being aware of the possible diagnosis. In addition, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?

Transfusion , Volume 34 (9) – Sep 1, 1994

Loading next page...
 
/lp/wiley/should-measures-be-taken-to-reduce-the-risk-of-human-parvovirus-b19-LU3qiAjI2F

References (32)

Publisher
Wiley
Copyright
1994 AABB
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.1994.34994378271.x
Publisher site
See Article on Publisher Site

Abstract

Should measures be taken to reduce the risk of human parvovirus (B 19) infection by transfusion of blood components and clotting factor concentrates? Over the last several years, a seemingly endless array of infectious agents have occasionally been transmitted by blood components andor plasma derivatives. We had thought that human parvovirus (HPV, B19) was responsible only for a self-limited common childhoodexanthem, with a brief period of viremia. It is now known to be a virus that is capable of prolonged viremia,' latency with reactivation,2and possible reinfe~tion.~.~ proporA small tion of persons have serious, sometimes chronic, impaired production of erythroid and, sporadically, other bone marrow cells, as well as manifestations in other systems. In this issue of TRANSFUSION, Luban5makes clear that a great deal can be learned quickly about a virus and its pathogenesis by using the tools of molecular virology. She correctly points out how much more difficult is the definition of the type and variety of recipients for whom HPV infection has the potential to be clinically important. Definition of the number of serious acute and chronic HPV cases, particularly if they are sporadic, depends first upon the physician's being aware of the possible diagnosis. In addition,

Journal

TransfusionWiley

Published: Sep 1, 1994

There are no references for this article.